ImmunityBio jumps as it answers FDA warning letter and details corrective steps
ImmunityBio shares are rising after the company said it submitted a comprehensive response to the FDA’s March 13, 2026 warning letter focused on allegedly misleading ANKTIVA promotion. The company also disclosed the update in a Form 8-K filed April 6, 2026, reducing near-term regulatory uncertainty for investors.
1. What’s moving the stock
ImmunityBio (IBRX) is trading higher as investors react to the company’s April 6, 2026 update that it submitted a detailed response to the FDA Office of Prescription Drug Promotion warning letter dated March 13, 2026. The FDA letter challenged certain ANKTIVA promotional communications (including a TV advertisement and a podcast) as misleading, and required a written response within a short timeframe; ImmunityBio’s filing and statement point to corrective actions already underway, which can be interpreted as lowering near-term headline risk. (immunitybio.com)
2. The regulatory backdrop investors are focused on
The FDA’s March 13, 2026 warning letter flagged how risk information and benefit claims were presented in ANKTIVA promotions and directed ImmunityBio to identify affected promotional materials, discontinue or correct them, and describe a plan to prevent recurrence. This matters because promotion-related enforcement can pressure commercial execution, create ongoing reputational overhang, and prompt investors to discount forward label-expansion narratives until the compliance path is clearer. (fda.gov)
3. What ImmunityBio says it did
In its April 6 communication, ImmunityBio said it provided the FDA a comprehensive response outlining immediate and planned corrective actions, including a broad review of promotional materials with legal and regulatory teams and steps aimed at ensuring future communications are accurate and balanced. The company also filed a Form 8-K referencing the same press release, giving the market a formal, time-stamped disclosure that it has engaged with the FDA’s process. (immunitybio.com)
4. What to watch next
Traders will likely monitor whether the FDA accepts ImmunityBio’s corrective plan without escalation, and whether any additional enforcement actions emerge tied to ANKTIVA promotion. Separately, investors are tracking ongoing regulatory progress for potential label expansion; ImmunityBio announced on March 9, 2026 that it resubmitted a supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease, which could become the next major fundamental catalyst if the review timeline becomes clearer. (ir.immunitybio.com)